LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of “Moderate Buy” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $94.67.

Several analysts recently issued reports on the stock. Barrington Research reissued an “outperform” rating and issued a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday. They issued a “neutral” rating and a $96.00 price target on the stock. JMP Securities boosted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Finally, Lake Street Capital began coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock.

LeMaitre Vascular Trading Down 1.0 %

LMAT opened at $91.24 on Wednesday. The company has a market cap of $2.05 billion, a P/E ratio of 60.42, a price-to-earnings-growth ratio of 2.45 and a beta of 0.88. The company has a fifty day moving average price of $88.42 and a two-hundred day moving average price of $81.05. LeMaitre Vascular has a 1-year low of $44.27 and a 1-year high of $93.32.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. During the same period in the prior year, the business earned $0.37 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, research analysts forecast that LeMaitre Vascular will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. boosted its stake in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares during the last quarter. YHB Investment Advisors Inc. bought a new stake in shares of LeMaitre Vascular in the 1st quarter worth approximately $36,000. GAMMA Investing LLC lifted its stake in LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares during the last quarter. USA Financial Formulas bought a new position in LeMaitre Vascular during the third quarter valued at $60,000. Finally, West Oak Capital LLC purchased a new stake in LeMaitre Vascular in the second quarter worth $58,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.